



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/13, C12P 21/08 A61K 39/395 // C12N 5/10	A1	(11) International Publication Number: WO 93/11238 (43) International Publication Date: 10 June 1993 (10.06.93)
(21) International Application Number: PCT/JP92/01583 (22) International Filing Date: 3 December 1992 (03.12.92) (30) Priority data: 3/323319 6 December 1991 (06.12.91) JP (71) Applicants (for all designated States except US): SUMITO- MO PHARMACEUTICALS COMPANY, LIMITED [JP/JP]; 2-8, Dosho-machi 2-chome, Chuo-ku, Osaka- shi, Osaka 541 (JP). BIOTEST PHARMA GMBH [DE/ DE]; Landsteinerstrasse 5, D-6072 Dreieich (DE). IN- NOTHERAPIE LABORTOIRES [FR/FR]; 1, boule- vard A.-Fleming, Poite Postale 1937, F-25020 Besançon Cédex (FR). (72) Inventors; and (75) Inventors/Applicants (for US only) : NAKATANI, Tomoyu- ki [JP/JP]; 1-23-6, Yuyamada, Kawanishi-shi, Hyogo- ken 661-01 (JP). GOMI, Hideyuki [JP/JP]; 1-11-12, Kou- tari, Nagaokakyou-shi, Kyoto-fu 617 (JP). WJDNES, John [FR/FR]; Rue de la Gratte, F-25720 Larnod (FR). NOGUCHI, Hiroshi [JP/JP]; 4-4-153, Seiwadai, Kawan- ishi-shi, Hyogo-ken 661-01 (JP).		(74) Agents: AOYAMA, Tamotsu et al.; Twin 21 Mid Tower, 1-61, Shiromi 2-chome, Chuo-ku, Osaka-shi, Osaka 540 (JP). (81) Designated States: US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: HUMANIZED B-B10, AN ANTI-IL2 RECEPTOR ANTIBODY (57) Abstract <p>A humanized antibody is provided, which is obtained by transplantation of the complementarity determining region of a mouse monoclonal antibody B-B10 specific to a human IL-2 receptor into a human antibody. The antibody has a very low antigenicity, and therefore, it is useful for treatment of carcinoma expressing IL-2 receptor.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

HUMANIZED B-B10, AN ANTI-IL2 RECEPTOR ANTIBODY

FIELD OF THE INVENTION

5 The present invention relates to a humanized
antibody specific to a human IL-2 receptor. More
particularly, it relates to a humanized antibody obtained
by transplantation of the complementarity- determining
region (hereinafter, referred to as CDR) of a mouse
monoclonal antibody B-B10 specific to a human IL-2 receptor
10 into a human antibody, and a composition comprising said
antibody as an active ingredient.

BACKGROUND OF THE INVENTION

 The structure and function of the antibody
related to the present invention will be first explained.
15 Namely, such structure and function are described in
details in Kabat et al.: Sequences of proteins of
immunological interest, 4th Ed., 1989, NIH, U.S.A. as well
as Roitt et al.: Immunology, 2nd Ed., 1989, Gower Medical
Publishing, U.S.A. & U.K.

20 The antibody (immunoglobulin) is an antigen-
specific glycoprotein as produced by B lymphocytes when a
subject is sensitized with an antigen which is a foreign
substance to the subject.. As the human immunoglobulin,
there are known 5 classes, i.e., IgG, IgM, IgA, IgD and

- 2 -

IgE. In case of IgG, it has two light chains (L chains) of polypeptide having a molecular weight of about 25,000 and two heavy chains (H chains) of polypeptide having a molecular weight of about 51,000. Between H-L chains and between H-H chains, there is usually present a disulfide bond connecting two chains. An amino acid sequence consisting of about 100 amino acids at N terminal of each of the H and L chains is antigen-specific and represents an antigen-binding site. This part is called a variable (V) region. Subsequent amino acid sequence consisting of 400 amino acids in H chain or 150 amino acids in L chain is called a constant (C) region which is identical among all immunoglobulins belonging to a Ig Class such as IgG or IgM Class, or those belonging to a subclass such as igG_1 or igG_2 . It is known that human IgG may have $C\kappa$ or $C\lambda$ in L chain and $C\gamma_1$, $C\gamma_2$, $C\gamma_3$ or $C\gamma_4$ in H chain. L and H chains having one of these identified partial structures are called κ , λ , γ_1 , γ_2 , γ_3 and γ_4 chain, respectively.

H and L chain contain "domain structures". For instance, H chain is composed of VH , CH_1 , CH_2 , CH_3 domains and hinge regions connecting CH_1 and CH_2 domains.

The variable region comprises four framework regions in which relatively conservative amino acid sequences are retained among various antibodies and three CDRs which are relatively variable in the amino acid

- 3 -

sequence among different antibodies. In one molecule of an antibody which comprises two H chains and two L chains, there are present six CDRs originated from VH and VL regions, which take steric configurations closely
5 approached one another to form an antigen binding site.

The summary of the structure and function of the antibody is as above.

The monoclonal antibody (hereinafter, referred to as "MAb") is widely used for diagnosis and therapy in the
10 medical field and as reagents, affinity column materials, etc. in the industrial field. The mouse MAb is readily obtained by the mouse/mouse hybridoma method.

For preparation of a human MAb which is more valuable for human therapy than a mouse MAb, various
15 improvements have been proposed but any reliable method for establishing a producible cell line with good reproducibility and high efficiency has not been established. Because of this reason, human MAb as clinically usable is quite restricted. Also, the
20 production of a human antibody to an antigen originated from a human being is generally impossible except any special case.

In case of a mouse, MAb specific to various antigens including antigens of human origin can be easily
25 obtained but on administration to a human being, a problem

- 4 -

of antigenicity occurs. Some attempts have been made to produce an antibody lowered in antigenicity to a human body from mouse MAb. Specifically, attempts are directed to the production of a humanized antibody wherein only a CDR, which is said to form an antigen-binding site, in the variable region of mouse MAb, is left and all the other regions are replaced by the human ones.

For instance, in the method as disclosed in EP-A-87302620, the CDR of mouse MAb is transplanted into the human MAb V region by the use of site specific mutation with a long oligonucleotide. As an example of obtaining a humanized antibody as explained above, there is known an attempt for humanization of rat MAb Campath-1 recognizing CDw52 antigen on human T cells (EP-A-89301291).

As one of mouse MAbs for which humanization would be effective, there is known anti-human IL-2 receptor antibody B-B10 (Japanese Patent Publication (Unexamined) No. 2-13371). This antibody is antagonistic to the binding of IL-2 to the IL-2 receptor on human T-cells and inhibits the IL-2 dependent growth of activated T-cells. It also inhibits the human mixed lymphocyte reaction. Accordingly, said MAb is useful for treatment and prevention of the diseases caused by graft-versus-host reaction or host-versus-graft reaction, prevention of rejection on the transplantation of bone marrow, kidney, heart, lung,

- 5 -

pancreas, skin, liver, etc., therapy of T-cell dependent allergy or autoimmune diseases (E.g., myocarditis, diabetes mellitus, myasthenia gravis, lupus erythematosus, Crohn disease, multiple sclerosis, AIDS, Meningitis, Arthritis) and therapy of tumors expressing IL-2 receptor such as T-cell leukemia.

In fact, the administration of B-B10 on the graft-versus-host reaction as produced after the bone marrow transplantation or the preventive administration of B-B10 on the rejection of the liver transplantation produces a certain effect (Blood, Vol. 75, 1017 (1990); Lancet, Vol. 335, 1596 (1990)).

On the practical therapy, however, the administration of B-B10 is carried out only for a short period of time, because of a concern to the antigenicity of mouse MAb. Also, there is a clinical example where an antibody to mouse MAb was found from a patient to whom mouse MAb was administered. The administration over a long period of time is thus quite difficult from the practical viewpoint. As understood from this, the administration of B-B10 is limited due to the fact that it is a kind of mouse MAb and the therapeutic effect is also restricted.

In order to solve the above problem, it is necessary to decrease the antigenicity originated from the mouse antibody by humanization. As to humanized

- 6 -

antibodies, there are present some other examples in addition to those as hereinabove mentioned. For instance, an anti-Tac antibody is humanized by transplantation of nine amino acid residues on the framework in addition to CDR, and as the result of the humanization, the activity is lowered to 1/3 (Proc. Natl. Acad. Sci. USA Vol. 86, 10029 (1989)). Also, the humanized antibodies to the gB glycoprotein and gD glycoprotein of herpes simplex virus are transplanted respectively with two amino acids residues and eight amino acid residues on the framework in addition to CDR, and their activities are respectively 1/2 and 1 in comparison with mouse MAb (Proc. Natl. Acad. Sci. USA, Vol. 88, 2869 (1991)). Further, the humanized antibody to the human CD4 is transplanted with one amino acid residue in addition to CDR, and its activity is 1/3 in comparison with mouse MAb (Proc. Natl. Acad. Sci. USA, Vol. 88, 4181 (1991)).

As understood from the above, it is necessary for obtaining a humanized antibody having an activity similar to mouse MAb to transplant not only CDR but also an amino acid residue(s) which would afford an important influence on the antigen-antibody binding in the framework of mouse MAb. However, such amino acid residue(s) are different depending upon the kind of the antibody; in fact, the examples as above recited shown that some amino acid

- 7 -

residues are common to them and some others are not. It is thus required to determine the necessary amino acid residue(s) on each antibody. Like the case of the humanized antibody to the gD glycoprotein of herpes simplex virus, such an approach as leaving the amino acid sequence on the framework expected to participate in the antigen-antibody binding as in mouse MAb. In this case, however, the same amino acid residue as in mouse MAb increase so that the antigenicity of mouse MAb is increased.

When the framework of mouse MAb contains one or more amino acid residues which rarely exist in human antibodies, they are, in principle, concerted to other amino acid residues highly common to human antibodies.

Thus, sixteen amino acid residues on the framework have been substituted in this case. As understood from the above, it is necessary for obtaining a humanized antibody to identify amino acid residue(s) on the framework which appear essential for retaining the activity and to transplant them to the human antibody together with CDR.

However, it is very difficult to pre-determine such essential amino acid residue(s). Accordingly, transplantation of all of the amino acid residues on the framework, which appear possibly involved in antigen-binding activity, is desirable in preparing humanized antibody. However, the humanized antibody thus prepared is

- 8 -

destined to include many amino acid residues derived from mouse antibody, and therefore, antigenicity of the humanized antibody may inevitably be high.

DISCLOSURE OF THE INVENTION

5 Under the circumstances as noted above, the present inventors attempted the humanization of mouse B-B10. As the result, it has been succeeded to produce humanized B-B10 having an activity similar to mouse B-B10 with transplantation of a minimum amino acid sequence in
10 the framework. Namely, the cDNA of the V region of the antibody was successfully cloned from the hybridoma cell line producing mouse B-B10 by a per se conventional procedure such as the polymerase chain reaction (PCR) method, and the amino acid sequence was determined. Then,
15 the V region of human antibody having a high homology to such amino acid sequence was selected, and the framework of this human antibody was bound with the B-B10 V region CDR and a part of the framework to design several kinds of the humanized B-B10 V region. Such humanized B-B10 is
20 different from mouse B-B10 in the amino acid residue of the framework of which a part was transplanted. The DNA sequence encoding said amino acid residues was synthesized, and a plasmid expressing humanized B-B10 was constructed. The plasmid was introduced into a mouse myeloma cell line
25 to obtain a humanized B-B10 producing cell.

- 9 -

Productivity of the antibody was increased by amplification of the antibody-encoding gene, and the resultant several humanized B-B10 antibodies were purified and evaluated on their activities. As a result, the amino acid residues on the framework, which have strong influence on the B-B10 activity and which are called "M5", were clarified. The most active humanized B-B10 was expected to be the one in which as much amino acid residues as possible on the framework of mouse B-B10, including M5, were transplanted. However, contrary to expectation, the evaluation of the activities revealed that humanized B-B10 obtained by minimum level of transplantation was most active as far as it includes M5. This humanized antibody (M5) is expected to be advantageous with respect to antigenicity, and yet it showed almost the same level of activity as that of mouse B-B10. The present invention is based on this finding.

Since the gene encoding humanized B-B10 has been determined, the preparation of various humanized B-B10 derivatives has become possible by means of recombinant DNA technology. Such B-B10 derivatives include Fv, Fab, and a fused protein consisting of the humanized B-B10 and a proteinaceous toxin or an enzyme.

The present invention is explained in more detail below.

- 10 -

The present invention provides humanized antibodies derived from mouse anti-human IL-2 receptor antibody, B-B10 MAb. One embodiment of the antibodies of the invention is defined by the following CDR in V region and partial amino acid sequences in the framework.

H chain V region

CDR1: SEQ ID No. 1

CDR2: SEQ ID No. 2

CDR3: SEQ ID No. 3

L chain V region

CDR1: SEQ ID No. 4

CDR2: SEQ ID No. 5

CDR3: SEQ ID No. 6

H chain V region

27th-30th amino acids: SEQ ID No. 7

94th amino acid: Arg

L chain V region

49th amino acid: Lys

The present invention includes a matured (perfect) humanized B-B10 antibody and its fragments such as Fv, Fab, (Fab)₂.

The humanized antibody and its fragment of the invention may contain an additional functional molecule. For instance, they may be bound to a functional molecule

- 11 -

such as a toxin (e.g. lysin), an enzyme, or a certain kind of cytokine.

BRIEF DESCRIPTIONS OF DRAWINGS

Fig. 1 shows DNA sequence encoding mouse B-B10 V region (H chain), and amino acid sequence encoded thereby.

Fig. 2 shows DNA sequence encoding mouse B-B10 V region (L chain), and amino acid sequence encoded thereby.

Fig. 3 shows comparison of the amino acid sequence of humanized B-B10M0 with the amino acid sequences of mouse B-B10, and human antibodies KAS and PAY which were used as templates. Position of mutation of M1-5 is also indicated. In M1-5, all of the amino acid residues shown in the figure are replaced by the amino acid residues of mouse B-B10. FR means framework.

Fig. 4 shows synthesized DNA sequence of humanized B-B10M0 V region (H chain). The framed sequence codes for V region. Other sequence comes from FK-001 antibody gene. The underline indicates the position of a primer used in the gene synthesis.

Fig. 5 shows synthesized DNA sequence of humanized B-B10M0 V region (L chain). The framed sequence codes for V region. Other sequence comes from FK-001 antibody gene. The underline indicates the position of a primer used in the gene synthesis.

- 12 -

Fig. 6 (a) shows humanized B-B10 H chain expression plasmid, and (b) shows humanized B-B10 L chain expression plasmid. The symbols, B-1a and dhfr respectively mean lactamase gene and dihydro folate reductase gene. VH, VK, C γ 1, and C κ respectively mean H chain V region gene, k chain V region gene, γ 1 chain constant region gene, and k chain constant region gene.

Fig. 7 shows SDS polyacrylamide gel electrophoresis of purified humanized B-B10. Lanes from left to right correspond to M0, M1, M2, M3, M4, M5, M123, M45, M12345, and mouse B-B10. H and L show the position of H chain and L chain respectively.

Fig. 8 shows inhibition of IL-2 dependent T-cell proliferation due to humanized B-B10. OD value on the ordinate is an index for the number of alive cells.

Fig. 9 shows inhibition of IL-2 dependent T-cell proliferation due to humanized B-B10. OD value on the ordinate is an index for the number of alive cells.

According to the present invention, humanized B-B10 antibody may be prepared by:

- 1) constructing a gene encoding a humanized antibody in which at least CDR in V region is derived from mouse B-B10 MAb and other part is derived from human antibody;

- 13 -

2) inserting the gene encoding the humanized antibody into a vector capable of existing in a host cell to obtain an expression plasmid;

3) transfecting the host cell with the plasmid
5 to establish a humanized B-B10 MAb producing cell; and

4) cultivating the cell to produce humanized B-B10 MAb.

The production of humanized antibody of the invention with the aid of recombinant DNA technology is
10 explained below.

(i) Isolation of RNA from the hybridoma producing mouse B-B10 antibody

Several conventional methods are available for isolation of RNA from the hybridoma producing mouse B-B10
15 antibody. However, the principal procedures common to them are cell lysis in the presence of a protein denaturing agent (e.g. guanidine thiocyanate), and isolation of RNA by phenol extraction or cesium chloride density-gradient centrifugation. Oligo-dT cellulose column chromatography
20 is useful for further purification, if desired. Standard protocol for the procedures is found in a text book, for example, J. Sambrook; Molecular Cloning, A Laboratory Manual; 2nd Ed., 1989, Cold Spring Harbor Laboratory Press, USA. Example 1 hereinafter described gives one example for
25 the isolation.

- 14 -

(ii) Isolation and Identification of V region
cDNA

V region cDNA may be prepared from the RNA isolated in (i) using a primer specific to mouse V region and a reverse transcriptase. The V region cDNA thus
5 obtained may be amplified by means of Polymerase Chain Reaction (PCR) using a specific primer. The primer specific to mouse V region may be prepared according to the teaching of M. J. Coloma, Biotechniques, Vol.11, 1991,
10 p.152; R. Orlandi et al, Proc. Natl. Aca. Sci. USA, Vol.86, 1989, p.3833; or L. Sastry, Proc. Natl. Aca. Sci. USA, Vol.86, 1989, p.5728. Detailed explanation for PCR is given in the aforementioned J. Sambrook's text, particularly in Chapter 14. The V region cDNA thus
15 obtained may be cloned using a plasmid or a phage vector. The amino acid sequence of the cloned cDNA may be determined by dideoxy sequencing (J. Messing, Method in Enzymology, Vol.101, 1983, p.20) or Maxam-Gilbert method (A. M. Maxam & W. Gilbert, Proc. Natl. Aca. Sci. USA,
20 Vol.74, 1977, p.560). Based on the DNA sequence determined, corresponding amino acid sequence can be deduced. Part of the deduced amino acid sequence can be confirmed to be correct by comparison with corresponding partial amino acid sequence of the antibody peptide, which
25 has been determined by a protein sequencer. The amino acid

- 15 -

sequence of mouse B-B10 V region thus identified is shown in Figs. 1 and 2.

(iii) Design of amino acid sequence of humanized B-B10 V region

5 A human antibody, into which the mouse B-B10 CDR is to be transplanted, may be selected using a database such as Genbank or EMBL. A human antibody V region having a high homology to the amino acid sequence of mouse B-B10 V region is selected. Specifically, KAS antibody for VH and
10 PAY antibody for Vk are recommended. As for the amino acid residues on the framework, which are to be transplanted like CDR, one can take it into consideration that the amino acid residues which is suspected to influence on the formation of CDR's three-dimensional structure have been
15 determined with some accuracy on the basis of the analysis of a three-dimensional structure of a known antibody (canonical structure model; Nature, Vol.342, 1989, p.877). Additional useful information is that the amino acid residues in the framework, which exist close to CDR, may
20 have influence on the CDR's three-dimensional structure. Three-dimensional structure of a designed humanized B-B10 V region can be predicted using an appropriate computer program, preferably BIOCES available from Sumitomo Chemical Company, Limited and Sumitomo Pharmaceuticals Company,
25 Limited. Exemplary design for humanized antibodies of the

- 16 -

invention is shown in Fig. 3 of the accompanying drawings and Example 5.

(iv) Construction of DNA encoding V region of humanized B-B10

5 A DNA encoding V region of humanized B-B10 may be constructed by a total synthesis or repeated PCR using a mouse B-B10 or human V region DNA as a template. Additional DNA sequences necessary for expression, such as signal sequence and intron, may be linked to the DNA
10 encoding V region of humanized B-B10 at the 5' or 3' terminal. Example 6 hereinafter described illustrates the synthesis of DNA for humanized B-B10 V region by means of PCR using a mouse B-B10 V region DNA as a template and linkage of the resultant DNA to the DNA encoding the V
15 region of human antibody FK-001 (Japanese Patent Publication (Unexamined) No. 267295/1988) at the 5' or 3' terminal.

 An arbitrary amino acid sequence in V region can be changed to a desired sequence using site-directed
20 mutagenesis in vitro.

 Various humanized B-B10 V region DNAs obtained in the manner as described above are illustrated in Example 7.

(v) Construction of expression plasmid for humanized B-B10

- 17 -

If necessary, a translation-initiating signal, a transcription-initiating signal (promoter), an enhancer, etc. may be added to the humanized B-B10 V region DNA. Specific examples of promoters and enhancers are, for example, SV40 (J. Mol. Appl. Genet., Vol.1, 1983, p.327), the promoter/enhancer derived from cytomegalovirus (Cell, Vol.41, 1985, p.521), LTR from Rous sarcoma virus (Proc. Natl. Aca. Sci. USA, Vol.76, 1982, p.6777). Example 6 demonstrates the use of the promoter/enhancer of the gene for human FK-001 antibody. Linkage of human B-B10 V region DNA at the downstream with a gene for a constant (c) region provides a humanized antibody gene.

Constant region genes are available from JCRB. The humanized B-B10 H chain and L chain may be introduced into separate or same vector(s) to construct an expression plasmid. Examples of the expression vectors are SV40-derived vector (J. Mol. Appl. Genet., Vol.1, 1982, p.327), and bovine papilloma virus vector (Proc. Natl. Aca. Sci. USA, Vol.79, 1982, p.7147). Examples 8 and 9 demonstrate the use of pSV2dhfr (Mol. Cell. Biol., Vol.1, 1981, p.854) and pUC118 (Methods Enzymol., Vol.153, 1987, p.3) respectively.

(vi) Transfection of humanized B-B10 expression plasmid

- 18 -

Humanized B-B10 antibody-producing cells capable of expressing humanized B-B10 antibody gene may be obtained by means of a conventional DNA introduction using an animal cell not producing antibodies, preferably mouse myeloma

5 cell. The expression plasmid for the humanized B-B10 antibody gene may be introduced, together with a marker plasmid if desired, into a host cell through conventional procedures such as red cell ghost method (Proc. Natl. Acad. Sci. USA., Vol.77, 1980, p.2163), DEAE-dextran method

10 (Nature, Vol.293, 1981, p.79), calcium phosphate method (Virology, Vol.52, 1973, p.456), protoplast fusion method (Cell, Vol.33, 1981, p.717), electroporation method (Proc. Natl. Aca. Sci. USA, Vol.81, 1984, p.7161), and lipofection method (Proc. Natl. Acad. Sci. USA, Vol.84, 1987, p.7413).

15 DNA-introduced cells may be selected by cultivating the transfected cells in a selective medium containing G-418 or mycophenolic acid. Humanized B-B10 antibody in a culture supernatant may be detected by enzyme immunoassay (e.g. ELISA), and a humanized B-B10 producing

20 cell can be selected from drug-resistant cells. By cultivating the humanized B-B10-producing cell, humanized B-B10 can be obtained from the supernatant and purified using conventional chromatography. Productivity of the antibody may be enhanced by using a marker capable of gene-

25 amplification and adding a selective drug to the culture

- 19 -

medium, whereby amplification of the antibody gene is induced. Examples 10, 12 and 13 demonstrate the construction of humanized B-B10 expression plasmid using an expression unit of FK-001 antibody gene, the establishment
5 of humanized B-B10 producing cell by transfection of mouse myeloma cell, Sp2/0-Ag14 (available from ATCC) as a host cell, and recovery of humanized B-B10.

Purified humanized B-B10 may be formulated by conventional methods usually employed in the production of
10 a biological preparation. In essence, the purified antibody is sterile-filtered, for instance, with a membrane filter, followed by addition of a stabilizer.

(vii) Evaluation of humanized B-B10

Enzyme immunoassay, particularly ELISA, may be
15 used for evaluation of humanized B-B10 (E. Harlow and D. Lane; Antibodies: A Laboratory Manual, 1988, Cold spring Harbor Laboratory, USA; especially Paragraph 14). The amount of the antibody present in a culture medium may be determined by ELISA which uses a plate on which an antibody
20 against H chain C region has been adsorbed.

Biological activity of humanized B-B10 may be measured by determining the inhibition of IL-2 dependent proliferation of activated human T cell as illustrated in Examples 11 and 14.

- 20 -

The humanized B-B10 antibody of the invention is parenterally administered with a dosage of about 0.05-500 mg for treatment and prevention of diseases caused by graft-versus-host reaction or host-versus-graft reaction, prevention of rejection on the transplantation of bone marrow, kidney, heart, lung, pancreas, skin, liver, etc., therapy of T-cell dependent allergy or autoimmune diseases (e.g. myocarditis, diabetes mellitus, myasthenia gravis, lupus erythematosus, Crohn disease, multiple sclerosis, AIDS, meningitis, arthritis), and therapy of tumors expressing IL-2 receptor such as T-cell leukemia.

ADVANTAGEOUS EFFECT OF THE INVENTION

1) Half-life of mouse Mab in blood is about 15 hours, when administered to human (J. Natl. Cancer Inst., Vol.80, 937, 1988), whereas half-life of human IgG1 is about 2 weeks. The humanized antibody of the invention is very close to human antibody, and therefore, may possibly have similar half-life to human antibody. It is expected that the humanized B-B10 has much longer half-life in blood and remains effective for a prolonged period of time when compared with mouse B-B10.

2) The effect described in the above item 1) enables to decrease frequency of administration and dosage of the antibody.

- 21 -

3) Antigenicity of humanized B-B10 is much less than mouse B-B10. As a matter of fact, administration of humanized antibody, Campath-1H, did not induce anti-Campath-1H antibody in two instances (Lancet, Vol.2, 1394, 1988).

Accordingly, it is expected that humanized B-B10, when administered to human, is not likely to induce undesirable neutralization antibody, contrary to mouse B-B10. This permits frequent administration of humanized B-B10 for a long time, which increases therapeutical effects and enlarges the scope of applications.

The present invention will be hereinafter explained in detail by way of examples, but is not limited to those examples.

Example 1

Extraction and Purification of RNA from a B-B10-Producing Hybridoma

Hybridomas which produce B-B10 was suspended in 4M guanidine thiocyanate (60 °C) and treated with a syringe attached with a 18G needle to lower the viscosity. To the suspension was added one equivalent of phenol (60 °C) and the mixture shaken vigorously. After the addition of 1/4 volume of 0.1 M sodium acetate (pH 5.2)/10 mM Tris-HCl (pH 7.4)/1 mM EDTA and 1/2 volume of a mixture of chloroform/isoamyl alcohol (24:1), the suspension was

- 22 -

shaked vigorously, ice-cooled and centrifuged. The aqueous phase was taken and RNA was recovered by ethanol precipitation.

Example 2

5 Cloning of cDNA encoding V Region of B-B10

Two cDNAs each encoding VH and Vk region of mouse B-B10 were synthesized using specific primer, amplified by PCR, cloned, and sequenced as follows. Primers "VHback" and "VHfor" which anneal to the N- and C-termini of VH respectively, and primers "Vkfor" and "Vkback" which anneal to N- and C- termini of Vk respectively, were synthesized using an Applied Biosystems Model 380A DNA synthesizer. Sequences of these primers are shown below.

VHback: SEQ ID No.10
15 SEQ ID No.11
VHfor: SEQ ID No.12
 SEQ ID No.13
Vkback: SEQ ID No.14
 SEQ ID No.15
20 VKfor: SEQ ID No.16

B-B10 RNA was primed with VHfor primer to yield B-B10 VH cDNA, which was followed by PCR using VHfor and VHback primers. B-B10RNA was primed with Vkfor primer to yield B-B10 Vk cDNA, which was followed by PCR using Vkfor and Vkback primers. The cDNA was synthesized in a 20 µl

25

- 23 -

reaction mixture containing 50 mM KCl, 10 mM Tris HCl (pH8.3), 1.5 mM MgCl₂, 0.001% gelatin, each 0.8 mM of dATP, dGTP, dCTP and dTTP, 2μl RNA, and 1μM primer in the presence of 20 units reverse transcriptase (RAV-2, Takara Shuzo) for 30 min at 42 °C. After heating the mixture at 95 °C for 5 min, PCR was carried out in a 100 μl reaction mixture containing 50 mM KCl, 10 mM Tris HCl (pH8.3), 1.5 mM MgCl₂, 0.001% gelatin, each 0.4 mM of dATP, dGTP, dCTP and dTTP using 1μM primer by repeating 40 times of a reaction cycle consisting of heating at 95 °C for 30 sec, 55 °C for 30 sec and 72 °C for 1 min. The products of PCR were then 5'-end phosphorylated using T4 polynucleotide kinase (Takara Shuzo) and cloned into the Hinc II site of plasmid vector pUC19. The DNA sequence was determined by dideoxy method using a commercially available primer for the vicinity of the multi-cloning sites and a Sequenase Version 2.0 DNA Sequencing Kit (United States Biochemical Corporation, USA) according to the manufacturer's recommended protocols. The identified sequences of DNA and deduced amino acid might be incorrect at the N and C terminal regions. However, a correct sequence of the N-terminal region of Vk was obtained without the aid of primer because the Vkbac primer annealed to the upper site from 5' terminal of Vk. The correct sequences were

- 24 -

thereafter obtained as described in Examples 3 and 4 and provided in the accompanying drawings, Figures 1 and 2.

Example 3

Confirmation of the Amino Acid Sequence of the N-terminal Regions of Mouse B-B10 VH by Means of Gas-phase Protein Sequencer

Purified mouse B-B10 antibody was mixed with an equivalent amount of a loading buffer (125 mM Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate(SDS), 10% mercaptoethanol, 0.01% bromophenolblue(BPB)). After heating at 100 °C for 5 min, the mixture was electrophoresed on 12.5% polyacrylamide gel (SDS-PAGE), electroblotted onto PVDF membrane (Millipore, USA) in a 10 mM CAPS (3-cyclohexylaminopropane sulfate, Dojin Chemicals, Inc.) and visualized by staining with Coomassie Brilliant Blue R 250 Wako Junyaku, Japan). The band containing H chain was excised and the N-terminal amino acid sequences of collected peptide fragments were determined by means of an Applied Biosystems model 470A/120A gas-phase protein sequencer (J.Biol.Chem., 262:10035 (1987)). The results are shown below.

VH N-terminal amino acid sequence: SEQ ID No.17

Example 4

Confirmation of the Amino acid Sequence of the C-terminal Regions of Mouse B-B10 VH and Vk

- 25 -

The DNA sequences each encoding the C-terminal region of mouse B-B10 VH and Vk were amplified by PCR, cloned and sequenced. Primers VH2, MIG-1, Vk2 and MIK-1 which anneal to VHCDR1, N-terminal region of CH1, VkCDR1 and N-terminal region of Ck, respectively, were synthesized. Sequences of these primers are shown below.

VH2: SEQ ID No.18

Vk2: SEQ ID No.19

MIG-1: SEQ ID No.20

10 MIK-1: SEQ ID No.21

B-B10 RNA was primed with MIG-1 primer to yield B-B10 VH cDNA, which was followed by PCR using VH2 and MIG-1 primers. B-B10 RNA was primed with MIK-1 primer to yield B-B10 Vk cDNA, which was followed by PCR using Vk2 and MIK-1 primers. The cDNA was synthesized in a 50 μ l of a reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH8.3), 1.5 mM MgCl₂, 0.001% gelatin, each 0.2 mM of dATP, dGTP, dCTP and dTTP, 2 μ l RNA, and 1 μ M primer in the presence of 20 units reverse transcriptase (RAV-2, Takara Shuzo) for 1 hr at 42 °C. After heating the mixture at 95 °C for 10 min, 10 μ l of the reaction mixture was subject to PCR, which was conducted in a 100 μ l reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH8.3), 1.5 mM MgCl₂, 0.001% gelatin, each 0.4 mM of dATP, dGTP, dCTP and dTTP, and 1 μ M primer by repeating 30 times of a reaction cycle

- 26 -

consisting of heating at 95 °C for 1 min, 50 °C for 1 min and 72 °C for 2 min. The products of PCR were separated by a gel-electrophoresis and the desired product was extracted from the gel and purified. The resultant product of PCR was 5'-end phosphorylated using T4 polynucleotide kinase (Takara Shuzo) and cloned into Hinc II site of plasmid vector pUC19. The cloned DNA was sequenced by dideoxy method using a commercially available primer for the vicinity of the multi-cloning sites and a Sequenase Version 2.0 DNA Sequencing Kit (Unite States Biochemical Corporation, USA) according to the manufacturer's recommended protocols. The identified DNA sequence and deduced amino acid sequence are contained in the sequences shown in Figures 1 and 2.

Example 5

Design for the Amino Acid Sequence of Humanized B-B10 VH and VK Regions

Prinas Data Base was searched for the VH region of human antibody having an amino acid sequence which has the highest homology with the amino acid sequence of mouse B-B10 VH region to select the VH region of human antibody KAS (63% homology). VK region of a human antibody PAY which has the highest homology with Vk region of mouse B-B10 Vk region (57.0 % homology) was also selected and obtained in the same manner. Humanized B-B10 V region was

- 27 -

designed by combining the frameworks of these human antibodies to mouse B-B10 CDR except that the amino acids located at Nos. 27 to 30 and 94 which are positioned within frameworks were remained to be those of mouse B-B10.

5 This is because the amino acids were selected from frameworks which affect on the structure of CDR according to the canonical structure model. The resultant humanized B-B10 was designated as M0. Variants were also obtained by changing amino acid(s) of humanized B-B10 to that of mouse.

10 Thus, by replacing the amino acid(s) of VH region of humanized B-B10 with mouse amino acid(s), following variants were prepared. M1: at No.48; M2 at Nos. 66 and 67; and M3 at No.105. By replacing the amino acids of Vk region of humanized B-B10 with mouse amino acid(s),

15 following variants were prepared. M4 at Nos. 1 and 3; and M5 at No. 49. In the variants in M1, 2, 3 and 5, amino acids to be changed were selected because they are close to the CDR and therefore may affect on the structure of CDR. Amino acid(s) which gives a significant difference between

20 mouse B-B10 and M0 in the comparison of the predicted steric structures obtained by BIOCES was considered to have a reverse effect on the activity and therefore it was changed to that of mouse. As a result, M4 and M5 were selected. The variants having the above M1, M2 and M3 was

25 designated as M123, that having the M4 and M5 designated as

- 28 -

M45, and that having the M1, M2, M3, M4 and M5 designated as M12345. The above-mentioned names were used for expressing amino acid variants themselves, antibodies containing the same, and strains producing the antibodies in common. The relationships between these amino acid sequences are provided in Figure 3. Amino acids were numbered according to the teaching of Kabat et al (Sequences of Proteins of Immunological Interest, 4th edition, 1987, NIH, USA).

10

Example 6Synthesis of Humanized B-B10 M0 by PCR

Humanized B-B10 VH and Vk genes were synthesized by PCR using cDNA encoding mouse B-B10 VH and Vk regions and a gene encoding FK-001 human antibody (Biotechnology, volume 7, pp. 805-810 (1989)). The DNA sequence of humanized B-B10 V region was designed as shown in Figure 4 and 5 so that a signal peptide and/or intron originated from a gene encoding FK-001 antibody might ligate to the 5' and 3' of the region encoding humanized B-B10 V region.

The resultant gene contained DNA encoding VH and the DNA encoding Vk, each of which can be isolated as a SacI-BalI fragment and Bam HI-HindIII fragment, respectively for the cloning. The primers shown in the Figures 4 and 5 were used to obtain mouse VH and Vk DNAs, and PCR was conducted using as the template a gene encoding FK-001 antibody,

25

- 29 -

successively. Primers within the V region can anneal to mouse V region gene within the CDR region. The conditions used for the PCR is the same as that described in Example 3. Short PCR products were synthesized and the neighboring two products were combined to obtain a template for the next PCR, and so on. Finally, PCR products containing the desired gene encoding the V region of humanized B-B10 were obtained and cloned into phage vector M13mp19 or plasmid vector pUC18. The DNA sequence of cloned PCR product was determined by dideoxy method using a commercially available primer (Takara Shuzo) for the vicinity of the multi-cloning sites and a Sequenase Version 2.0 DNA Sequencing Kit (United States Biochemical Corporation, USA) according to the manufacturer's recommended protocols.

The synthesized gene encoding humanized B-B10 VH region was excised as a SacI-BalI fragment and inserted into the SacI-BalI site of a VH gene fragment of FK-001 antibody, and finally, was cloned into pUC18 as a 5.2 kb BamHI-HindIII fragment containing FK001 VH promoter, VH region-encoding gene of humanized B-B10, and IgH enhancer. The resultant plasmid was designated as plasmid pHB-B10VHEM0.

Plasmid pHB-B10VkM0 was constructed by inserting a 1.5 kb BamHI-BamHI fragment containing FK-001 Vk gene promoter to a BamHI site of plasmid pUC18 which comprises

- 30 -

humanized B-B10 Vk region-encoding gene cloned into the BamHI-HindIII site.

Example 7

5 Introduction of Mutations M1, M2, M3, M4 and M5
 into VH and VK Regions of Humanized B-B10 by In Vitro Site-
 specific Mutagenesis

 A 5.2 kb BamHI-HindIII fragment containing VH
gene of B-B10, H-chain promoter, and H-chain enhancer was
obtained by digesting plasmid pHB-B10VHEMO with restriction
10 enzymes BamHI and HindIII, subjecting to the
electrophoresis on agarose gel, and extracting the DNA
fragment by GeneClean II.

 The DNA fragment was then inserted into BamHI-
HindIII site of charomid pUC118 (Takara Shuzo) to obtain
15 plasmid pHB-B10VHE (118). In the same manner as above,
plasmid pHB-B10Vk (118) was obtained by transferring 2.1 kb
SacI-HindIII fragment containing Vk gene of plasmid pHB-
B10VkM0 to pUC118. These plasmids were transformed into
E. coli MV1184 (Nihon Gene). The resultant transformants
20 were transfected with helper phage M13K07 (Takara Shuzo)
and cultured to give phage-like particles containing
circular single-stranded DNA. After the purification of
phage-like particles, the circular single-stranded DNAs
contained therein were extracted and purified to use as a
25 template for the in vitro site-specific mutagenesis. The

- 31 -

preparation of the circular single-stranded DNA was conducted according to the protocol attached to the pUC118 products from the supplier. DNA primers used for the in vitro site-specific mutagenesis were synthesized and purified. Nucleotide sequences of these DNAs are shown below.

Primer for mutation M1: SEQ ID No.22

Primer for mutation M2: SEQ ID No.23

Primer for mutation M3: SEQ ID No.24

10 Primer for mutation M4: SEQ ID No.25

Primer for mutation M5: SEQ ID No.26

In vitro site-specific mutagenesis was carried out using primer M1, M2 or M3 when the template was phB-B10VHE(118), and primer M4 or M5 when the template was phB-B10Vk(118). The primer and the template was mixed and incubated at 70 °C for 3 min, and then at 37 °C for 30 min for the annealing. The annealed product was then reacted in the presence of dCTP α S, 6 units of Klenow fragment and 6 units of T4 DNA ligase at 16 °C for 15 hr for the elongation and ligation and the unreacted template DNAs were removed. The template DNA was nicked by treating with restriction enzyme NciI (5 units) at 37 °C for 90 min. Most of the template DNAs were removed by treating with 50 units of ExoIII nuclease at 37 °C for 30 min. At the end of the process, the resultant product was reacted in the

- 32 -

presence of 3 units E. coli DNA polymerase I and 2 units of T4 DNA ligase at 16 °C for 3 hr to obtain a mutation-introduced circular double-stranded DNA. In the above procedures, reagents, buffers, and column for purification were obtained from Oligonucleotide-directed in vitro mutagenesis system version 2 (Amersham, Inc.) and used according to the protocol provided by the supplier. The reaction mixture containing the mutation-introduced DNA was used to transform into E. coli JM109 to prepare plasmid DNA. The DNA was used to confirm the DNA sequence at the site of mutation by means of dideoxy sequencing method. For the sequencing, the above-mentioned M1, M2, M3, M4 or M5 primer, or commercially available primer (Takara Shuzo) in the vicinity of the multi-cloning site of pUC 19 was used as a primer and Sequenase Version 2.0 DNA Sequencing Kit (United states Biochemical Corporation, USA) was used for the reaction. These are used according to the protocol provided by the supplier. Multiple mutagenesis for M123 and M45 were conducted by repeating the above-mentioned procedures. The sites of mutations are given in Figure 3.

Example 8

Construction of H chain expression plasmid

Plasmids pH-B10VHEM0, M1, M2, M3, and M123 each containing 5.2kb BamHI-Hind III fragment which encodes VH gene of various B-B10, H chain promoter, and H chain

- 33 -

enhancer were digested with Bam HI and Hind III, and the resultant fragments were subjected to agarose gel electrophoresis to separate the above-noted desired fragment, which was then extracted and purified by means of
5 Geneclean II. Another plasmid containing a separately cloned gene encoding the constant region of human γ 1 chain (C γ 1) was digested with Hind III and EcoRI and subjected to agarose gel electrophoresis to separate 16.9kb Hind III-EcoRI fragment containing C γ 1 gene, which was then
10 extracted and purified by means of Geneclean II. In the same manner as above, 4.2kb Bam HI-EcoRI fragment was separated from plasmid pSV2dhfr and purified.

The above-noted three DNA fragments were combined and linked together using T4 DNA ligase to obtain plasmids
15 phB-B10dhfr HG1M0, M1, M2, M3, and M123 which express various B-B10 H chains.

Example 9

Construction of k chain expression plasmid

Plasmid containing the cloned FK-001 k chain gene
20 (Biotechnology, Vol.7, 1989, pp.805-810) was digested with restriction enzyme Hind III, and the digest products were electrophoresed on agarose gel to separate 5.6 kb Hind III-Hind III fragment containing k chain constant region (Ck) gene, which was then extracted and purified using Geneclean
25 II. Plasmids phB-B10Vkm0, M4, M5 and M45 each containing a

- 34 -

Vk gene of various B-B10 were digested with restriction enzyme Hind III followed by BAP treatment. The plasmids and the 5.6kb Hind III- Hind III fragment were treated with T4 DNA ligase, resulting in insertion of the 5.6kb Hind III-Hind III fragments into the Hind III site of each of the plasmids to obtain expression plasmids of various B-B10K chains, phB-B10HKM0, M4, M5 and M45.

Example 10

Establishment of various B-B10 antibodies producing cell lines by lipofectin method

Mouse myeloma cell line Sp2/0-Ag14 (Sp2/0, ATCC CRL-1581) was cultured in Dulbecco's modified Eagle's medium (DMEM, Nissui, Japan) supplemented with 10% fetal calf serum (FCS, Hyclone, USA) until it reached to logarithmic growth phase. From the culture, 5×10^6 cells were harvested by centrifugation, suspended in 0.5ml of serum-free medium (Celgrosser H, Sumitomo Pharmaceuticals) and placed into a well on a 6-well plate. Ten μ g of each of H chain expression plasmids, 10 μ g of L chain expression plasmid, and 5 μ g of pSV2neo were digested with restriction enzyme PvuI (Takara Shuzo) to generate linear DNAs, and then ethanol precipitated to recover the DNAs. The DNAs were suspended in 250 μ l of Celgrosser H.

Fifty μ l of lipofectin was diluted with 200 μ l of Celgrosser H, and mixed with the DNA solution above to

- 35 -

prepare the DNA/lipofectine complex. The DNA/lipofectin complex was dropwise added to the cell on 6-well plate, and the resulting mixture was incubated at 37°C under 5% CO₂ atmosphere for 7 hours. The cell was harvested, suspended in DMEM containing 10% FCS at a cell density of 5-10x10⁴/ml, and the suspension was dispensed in an amount of 100 µl per well on a 96-well plate. After 1-2 days, 100 µl of DMEM containing 800 µg/ml G-418 (Gibco, USA) and 10% FCS was added to each well. Thereafter, half of the medium was replaced with DMEM containing 400 µg/ml G-418 and 10% FCS every 2-3 days. Eight G-418 resistant colonies were found after about 2 weeks cultivation. Amount of the antibody in culture supernatant from each well was determined by Enzyme-linked immunosorbent assay (ELISA) as described in the following Example, and the wells which contained relatively high concentration of antibody were selected, and the cells from such wells were pooled for use as the antibody-producing cell.

Example 11

Determination of the amount of humanized B-B10 (human IgG (γ, k)) by ELISA

Determination of the amount of humanized B-B10 (human IgG (γ, k)) was accomplished as follow.

Anti-human IgG (γ chain) antibody (Cappel, USA) was dissolved in phosphate buffer (pH7.2, NaCl (8g/l), KCl

- 36 -

(0.2g/l), $\text{NaHPO}_4 \cdot 12\text{H}_2\text{O}$ (2.99g/l) and KH_2PO_4 (0.2g/l)) (PBS) at a concentration of 10 $\mu\text{g/ml}$, and placed on 96-well microplate (Falcon, USA) ("microplate") in an amount of 100 μl per well and then incubated at 37°C for 2 hours.

5 One hundred-twenty μl of PBS solution containing 1% bovine serum albumin (BSA) was added to each well and incubated at 37°C for 2 hours to block the protein-unbound area on the microplate.

10 Samples to be assayed for the amount of the antibody were suitably diluted with PBS containing 0.05% Tween 20 (hereinafter referred to as PBST), and added to each well at a ratio of 100 μl per well and incubated at 37°C for 2 hours. After the incubation, samples were removed and wells were washed 3 times with PBST followed by
15 the addition of 100 μl per well of the second antibody solution and subsequent incubation at 37°C for 2 hours. As the second antibody, phosphatase-labeled affinity-purified anti-human immunoglobulin k chain antibody (Tago, USA) was utilized. After removing the second antibody and washing 3
20 times with PBST, 100 μl of color-developing substrate (1mg/ml disodium P-nitrophenylphosphate in 10% diethanolamine buffer (pH 9.1) containing NaN_3 (0.2mg/ml) and $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ (0.1mg/ml)) was added to each well and reacted at 37°C. After the reaction, optical density of

- 37 -

each well was measured at 405 nm using Multiscan (Titertek).

This assay only allows the measurement of the normal human Ig in which γ chain and k chain associate each other.

Example 12

Amplification of the antibody gene by the use of MTX and the increased production of the antibody

The antibody-producing cell described in the preceding Example was suspended in DMEM/10% FCS containing 50nM MTX (methotrexate, Gibco, USA) at $1-5 \times 10^5$ cells/ml, and the 100-200 μ l aliquot was dispensed in each well on 96-well multiplate and then cultured at 37°C under 5% CO₂ atmosphere. After about 2 weeks cultivation, the amount of the antibody in culture supernatant from each well was determined by ELISA in accordance with Example 11.

Cells were collected only from the wells which displayed a high OD value, i.e., a high production level of the antibody, and cultured in larger scale to establish a 50nM MTX-resistant cell line. Similarly, a 100nM, 200nM, or 400nM MTX-resistant cell line was established in the same manner as in the 50nM-resistant cell line.

Antibody concentration of the culture supernatant from each of the cell lines was determined by ELISA using as a standard purified MO antibody which had been affinity-

- 38 -

purified through Protein A-column as described in the subsequent Example.

The results are shown in the following Table 1.

Table 1

5	Antibody produced	<u>Concentration of antibody ($\mu\text{g/ml}$)</u>				
		0	50	100	200	400 (nMMTX)
	M0	0.8	7.4	8.7	14.7	-
	M1	not determined	2.6	-	-	3.6
10	M2	0.1	2.7	-	9.0	-
	M3	0.1	0.3	-	1.0	-
	M4	0.3	3.5	-	-	9.5
	M5	0.2	3.4	-	-	5.3
	M123	1.1	4.0	-	8.0	-
15	M45	0.2	1.8	-	1.7	-
	M12345	0.7	1.8	-	-	4.5

In these cell lines, an increased amount of the antibody was produced with a cell line of increased MTX-resistance. These MTX-resistant cell lines were cultured in larger scale and finally subcultivated once in serum-free medium (Cellgrowther-H, Sumitomo Pharmaceuticals) to obtain serum-free culture supernatant.

Example 13

25

Purification of Antibodies

Serum-free culture supernatant containing various B-B10 antibodies was filtered through filter unit (Nalge,

- 39 -

USA) having a pore size of 0.22 μ m and applied to Protein A-cellophaine column (0.5ml) (Seikagaku Kogyo, Japan) at a flow rate of 1-2ml/min. After washing the column with 10ml of Immuno PureTM Binding Buffer (Pierce, USA), the

5 antibodies bond to the column were eluted with 2ml of Immuno PureTM Elution Buffer (Pierce, USA). The eluent was neutralized with 0.2ml of 1M Tris-HCl (pH8.0), dialized against PBS, and sterilized by filtration using a filter having a pore size of 0.22 μ m to obtain purified B-B10.

10 Colorimetric analysis using BCATM Protein Assay Reagent (Pierce, USA) and purified bovine IgG (BioRad, USA) as a standard determined a protein content of the purified B-B10. The results are shown in Table 2.

Table 2

	Antibody	Volume of Culture Supernatant (ml)	Final Volume (ml)	Protein Concentration (μ g/ml)	Protein Content (μ g)
15					
20	M0	70	2.8	105	294
	M1	130	2.8	76	193
	M2	130	1.0	370	370
	M3	270	2.8	99	277
	M4	130	2.8	470	1316
25	M5	130	2.8	129	361
	M123	150	2.8	92	258
	M45	310	2.8	183	512
	M12345	140	2.8	119	333

- 40 -

The above samples were subjected to SDS polyacrylamide gel electrophoresis according to the method described in Example 3. All of the samples except M123 showed no band other than H and L chain bands, which
5 revealed that the samples had been sufficiently purified. The amount of the contaminant which caused the extra band observed in M123 was very small, and therefore, it is thought harmless in evaluating the activity of the sample.

Example 14

10 Evaluation of biological activities of various variant B-B10 antibodies

Biological activities of various purified B-B10 obtained in the preceding Examples were studied. Evaluation of biological activities of various B-B10 was
15 carried out by comparing their activities in inhibiting proliferation of IL-2 dependent human activated T cells. Thus, human T cells activated by phytohemagglutinin (PHA) and recombinant human IL-2 (Colaborative Research, USA) were plated onto 96-well multiplate (Falcon, USA) for cell
20 culture at final concentrations of $4-10 \times 10^4$ cells/100 μ l/well and 0.25ng/100 μ l/well, respectively. After addition of B-B10 samples of various concentrations, the plate was incubated at 37°C for three days under 5% CO₂. To each of the wells was added 20 μ l of 2.5mg/ml MTT (3-(4,5-
25 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide,

- 41 -

suspended in PBS), and four-hour cultivation was conducted at 37°C under 5% CO₂. Formazan generated in living cells was dissolved in 40mM HCl/isopropanol which had been added to the wells at 100μl/well. OD₅₇₀ for each well was

5 determined using OD₆₃₀ as a reference and used as an indication of the number of living cells. The results are shown in Fig. 8, which shows that Proliferation of T cells is inhibited depending on the concentration of B-B10.

10 Among humanized B-B10 antibodies, M5 showed the highest inhibitory activity, which was estimated as nearly equal to that of mouse B-B10 after comparison of their working concentrations. M5 activity was higher than those of multiple variants M45 and M12345 containing M5.

- 42 -

SEQ ID NO: 1

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 5TOPOLOGY: Linear
MOLECULE TYPE: PeptideAsp Thr Tyr Met His
5

5

SEQ ID NO: 2

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 17TOPOLOGY: Linear
MOLECULE TYPE: PeptideArg Ile Asn Pro Thr Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe
5 10 15
Gln Gly
17

SEQ ID NO: 3

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 9TOPOLOGY: Linear
MOLECULE TYPE: PeptideArg Gly Asp Ala Met Tyr Phe Asp Val
5

9

SEQ ID NO: 4

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 11TOPOLOGY: Linear
MOLECULE TYPE: PeptideArg Ala Ser Gln Thr Ile Gly Thr Ser Ile His
5 10

11

SEQ ID NO: 5

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 7

- 43 -

TOPOLOGY: Linear
MOLECULE TYPE: Peptide

Tyr Ala Ser Glu Ser Ile Ser
5

7

SEQ ID NO: 6

SEQUENCE LENGTH: 9
SEQUENCE TYPE: Amino acid

TOPOLOGY: Linear
MOLECULE TYPE: Peptide

Gln Gln Ser Ser Ser Trp Pro Leu Thr
5

9

SEQ ID NO: 7

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 4

TOPOLOGY: Linear
MOLECULE TYPE: Peptide

Phe Asn Ile Lys

4

SEQ ID NO: 8

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 118

TOPOLOGY: Linear
MOLECULE TYPE: Peptide

Glu	Val	His	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	
				5					10					15	
Ser	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Phe	Asn	Ile	Lys	
				20					25					30	
Asp	Thr	Tyr	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	
				35					40					45	
Glu	Trp	Met	Gly	Arg	Ile	Asn	Pro	Thr	Asn	Gly	Asn	Thr	Lys	Tyr	
				50					55					60	
Asp	Pro	Lys	Phe	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Glu	Ser	
				65					70					75	
Thr	Asn	Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	
				80					85					90	
Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Arg	Arg	Gly	Asp	Ala	Met	Tyr	Phe	
				95					100					105	
Asp	Val	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser		118	
				110					115						

- 44 -

SEO ID NO: 9

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 107

TOPOLOGY: Linear
MOLECULE TYPE: Peptide

[illegible]

SEQ ID NO: 10

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 22 base pairs

MOLECULE TYPE: Synthetic DNA

AGGTCAAAC T GCAGCAGTCA GG 22

SEQ ID NO: 11

TYPE: Nucleic acid
SEQUENCE LENGTH: 22 base pairs

MOLECULE TYPE: Synthetic DNA

AGGTGCAGCT TCTCGAGTCT GG 22

SEQ ID NO: 12

TYPE: Nucleic acid
SEQUENCE LENGTH: 20

MOLECULE TYPE: Synthetic DNA

- 45 -

ACGGTGACCG TGGCGCCTTG 20

SEQ ID NO: 13

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 20

MOLECULE TYPE: Synthetic DNA

ACGGTGACCG AGGAGCCTTG 20

SEQ ID NO: 14

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 16

MOLECULE TYPE: Synthetic DNA

GCTGACACAG TCTCCA 16

SEQ ID NO: 15

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 16

MOLECULE TYPE: Synthetic DNA

GATCACCCAG ACTCCA 16

SEQ ID NO: 16

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 15

MOLECULE TYPE: Synthetic DNA

CTCCAGCTTG GTCCC 15

SEQ ID NO: 17

SEQUENCE TYPE: Amino acid
SEQUENCE LENGTH: 20

TOPOLOGY: Linear
MOLECULE TYPE: Peptide

```
Glu Val Gln Leu Gln      Gln Ser Gly Ala Glu Leu Val Lys Ser Gly
              5             10            15
Ala Ser Val Lys Leu                20
          20
```

- 46 -

SEQ ID NO: 18

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 24

MOLECULE TYPE: Synthetic DNA

AACATTAAAG ACACCTATAT GCAC 24

SEQ ID NO: 19

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 28

MOLECULE TYPE: Synthetic DNA

CAGTCAGACC ATTGGCACAA GCATACAC 28

SEQ ID NO: 20

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 24

MOLECULE TYPE: Synthetic DNA

AGGGAAATAG CCCTTGACCA GGCA 24

SEQ ID NO: 21

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 24

MOLECULE TYPE: Synthetic DNA

GACATTGATG TCTTTGGGGT AGAA 24

SEQ ID NO: 22

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 28

MOLECULE TYPE: Synthetic DNA

GATTAATTCT TCCTATCCAC TCCAGGCC 28

SEQ ID NO: 23

SEQUENCE TYPE: Nucleic acid
SEQUENCE LENGTH: 28

- 47 -

MOLECULE TYPE: Synthetic DNA

GCTGTAATAG TGGCCTTGCC CTGGAAC

28

SEQ ID NO: 24

SEQUENCE TYPE: Nucleic acid

SEQUENCE LENGTH: 28

MOLECULE TYPE: Synthetic DNA

GACCAGGGTG CCTGCGCCCC AGACATCG

28

SEQ ID NO: 25

SEQUENCE TYPE: Nucleic acid

SEQUENCE LENGTH: 28

MOLECULE TYPE: Synthetic DNA

ACTGAGTCAG GAGGATGTCC CCGTAGGC

28

SEQ ID NO: 26

SEQUENCE TYPE: Nucleic acid

SEQUENCE LENGTH: 28

MOLECULE TYPE: Synthetic DNA

CTCAGAAGCA TATTTTATGA GAAGCCTT

28

- 48 -

CLAIMS

1. A humanized antibody having a specific binding activity to human IL-2 receptor and comprising a variable region including complementarity-determining regions (CDR) and partial frameworks, their amino acid sequences being as follows:

H chain V region

CDR1: SEQ ID No. 1

CDR2: SEQ ID No. 2

10 CDR3: SEQ ID No. 3

L chain V region

CDR1: SEQ ID No. 4

CDR2: SEQ ID No. 5

CDR3: SEQ ID No. 6

15 H chain V region

27th-30th amino acids: SEQ ID No. 7

94th amino acid: Arg

L chain V region

49th amino acid: Lys

20 2. A humanized antibody according to claim 1, wherein the variable region has the following amino acid sequence:

H chain V region: SEQ ID No. 8

- 49 -

L chain V region: SEQ ID No. 9

3. A humanized antibody according to claim 1 or 2, which comprises a matured antibody molecule, (Fab')₂, Fab or Fv.

5 4. A humanized antibody according to claim 1, 2 or 3, which is bound with a functional molecule.

10 5. A process for producing a humanized antibody, which comprises preparing a plasmid expressing a humanized antibody according to claim 1, 2, 3 or 4, introducing the plasmid into a host cell, obtaining a stable transformant cell and cultivating the resulting cell producing the humanized antibody.

6. A process according to claim 5, wherein the host cell is an animal or human cell.

15 7. A medicine in a dosage form for parenteral administration, which comprises as an essential component a humanized antibody according to claim 1, 2, 3 or 4.

1/9

DRAWINGS

Fig 1

```
      10      20      30      40      50      60
GAGGTGCAGCTGCAGCAGTCAGGGGCAGAGCTTGTGAAGTCAGGGGCCCTCAGTCAAGTTG
GluValGlnLeuGlnGlnSerGlyAlaGluLeuValLysSerGlyAlaSerValLysLeu

      70      80      90     100     110     120
TCCTGTACAGCTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGG
SerCysThrAlaSerGlyPheAsnIleLysAspThrTyrMetHisTrpValLysGlnArg

     130     140     150     160     170     180
CCTGAACAGGGCCTGGAGTGGATTGGAAGAATTAATCCTACGAATGGTAATACTAAATAT
ProGluGlnGlyLeuGluTrpIleGlyArgIleAsnProThrAsnGlyAsnThrLysTyr

     190     200     210     220     230     240
GACCCGAAGTTCAGGGCAAGGCCACTGTGACAGCAGACACATCCTCCAACACAGCCTAC
AspProLysPheGlnGlyLysAlaThrValThrAlaAspThrSerSerAsnThrAlaTyr

     250     260     270     280     290     300
CTGCAGCTCGGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGCTAGGAGGGGG
LeuGlnLeuGlySerLeuThrSerGluAspThrAlaValTyrTyrCysAlaArgArgGly

     310     320     330     340     350
GATGCCATGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCA
AspAlaMetTyrPheAspValTrpGlyAlaGlyThrThrValThrValSerSer
```

2/9

Fig 2

10 20 30 40 50 60
GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

70 80 90 100 110 120
TTCTCCTGCAGGGCCAGTCAGACCATTGGCACAAGCATACACTGGTATCAGCGAAGAACA
PheSerCysArgAlaSerGlnThrIleGlyThrSerIleHisTrpTyrGlnArgArgThr

130 140 150 160 170 180
AATGGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCC
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerIleSerGlyIleProSer

190 200 210 220 230 240
AGGTTTAGTGGCAGTGGATCAGGGACAGATTTTACTCTTAGCATCAACAGTGTGGAGTCT
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnSerValGluSer

250 260 270 280 290 300
GAAGATATTGCAGATTATTACTGTCAACAAAGTAGTAGCTGGCCGCTCACGTTCCGTGCT
GluAspIleAlaAspTyrTyrCysGlnGlnSerSerSerTrpProLeuThrPheGlyAla

310 320
GGGACCAAGCTGGAGCTGAAA
GlyThrLysLeuGluLeuLys

3/9

Fig 3

<VH>

	FR1	CDR1	FR2	M1
mB-B10	EVQLQQSGAELVKSGASVKLSCTASGFNIK	DTYMH	WVKQRPEQG	GLEWIG
hB-B10	EVHLVQSGAEVKKPGSSVKVSCKASGFNIK	DTYMH	WVRQAPGQG	GLEWMG
KAS	EVHLVQSGAEVKKPGSSVKVSCKASGGTFS	SYAIS	WVRQAPGQG	GLEWMG

	CDR2	M2	FR3
mB-B10	RINPTNGNTKYDPKFQG	KATVTADTSSNTAYLQLGSLT	SED TAVYYCAR
hB-B10	RINPTNGNTKYDPKFQG	RVTITADESTNTAYMELRSLR	SDDTAMYYCAR
KAS	GIPIFGQANYAQKFQG	RVTITADESTNTAYMELRSLR	SDDTAMYYCAK

	CDR3	FR4	M3
mB-B10	RGDAMY---FDV	WGAGTTVT	VSS
hB-B10	RGDAMY---FDV	WGQGT	LVT VSS
KAS	EGYGDYGRPFDF	WGQGT	LVT VSS

<Vk>

	FR1	M4	CDR1	FR2	M5
mB-B10	DILLTQSPAILSVSPGERVSFSC	RASQTIGTS-IH	WYQRR	TNGSPRLLIK	
hB-B10	EIVLTQSPGTLSLSPGERATLSC	RASQTIGTS-IH	WYQQR	PGQAPRLLIY	
PAY	EIVLTQSPGTLSLSPGERATLSC	RASQSVSSSYLA	WYQQR	PGQAPRLLIY	

	CDR2	FR3
mB-B10	YASESIS	GIPSRFSGSGSGTDFTLSINSVESEDIADYYC
hB-B10	YASESIS	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
PAY	GASSRAT	GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC

	CDR3	FR4
mB-B10	QQSSSWPLT	FGAGTKLELK
hB-B10	QQSSSWPLT	FGQGTKVEIK
PAY	QQYGSSPLT	FGQGTKVEIK

4/9

	10	20	30	40	50	60
5'	GAGGAGCTCC	AGACAATGTC	TGTCTCCTTC	CTCATCTTCC	TGCCCCGTGCT	GGGCGTCCCA
3'	CTCCTCGAGG	TCTGTTACAG	ACAGAGGAAG	GAGTAGAAGG	ACGGGCACGA	CCCGGAGGGT
	70	80	90	100	110	120
	TGGGGTCAGT	GTCAGGGAGA	TGCCGTATTC	ACAGCAGCAT	TCACAGACTG	AGGGGTGTTT
	ACCCCAGTCA	CAGTCCCTCT	ACGGCATAAG	TGTCGTCTGA	AGTGTCTGAC	TCCCCACAAA
	130	140	150	160	170	180
	CACTTTGCTG	TTTCCTTTTG	TCTCCAGGTG	TCCTGTCA	GA GGTGCACCTG	GTCCAGTCAG
	GTGAAACGAC	AAAGGAAAAC	AGAGGTCCAC	AGGACAGTCT	CCACGTGGAC	CAGGTCAGTC
	190	200	210	220	230	240
	GGGCAGAGGT	CAAGAAGCCA	GGGTCCTCAG	TCAAGGTCTC	CTGTAAGGCT	TCTGGCTTCA
	CCCGTCTCCA	GTTCTTCGGT	CCCAGGAGTC	AGTTCCAGAG	GACATTCCGA	AGACCGAAGT
	250	260	270	280	290	300
	ACATTAAAGA	CACCTATATG	CACTGGGTGA	GGCAGGCCCC	TGGGCAGGGC	CTGGAGTGGA
	TGTAATTTCT	GTGGATATAC	GTGACCCACT	CCGTCCGGGG	ACCCGTCCCG	GACCTCACCT
	310	320	330	340	350	360
	TGGGAAGAAT	TAATCCTACG	AATGGTAATA	CTAAATATGA	CCCGAAGTTC	CAGGGCAGGG
	ACCCTTCTTA	ATTAGGATGC	TTACCATTAT	GATTTATACT	GGGCTTCAAG	GTCCCCGTCCC
	370	380	390	400	410	420
	TCACTATTAC	AGCAGACGAG	TCCACAAACA	CAGCCTACAT	GGAGCTGAGG	AGCCTCAGGT
	AGTGATAATG	TCGTCTGCTC	AGGTGTTTGT	GTCGGATGTA	CCTCGACTCC	TGGGACTCCA
	430	440	450	460	470	480
	CTGATGACAC	TGCCATGTAT	TACTGTGCTA	GGAGGGGGGA	TGCCATGTAC	TTCCATGTCT
	GACTACTGTG	ACGGTACATA	ATGACACGAT	CCTCCCCCCT	ACGGTACATG	AAGCTACAGA
	490	500	510	520	530	
	GGGGCCAAGG	CACCCTGGTC	ACCGTCTCCT	CAGGTAAGAA	TGGCCAAGCT	TG 3'
	CCCCGGTTCC	GTGGGACCAG	TGGCAGAGGA	GTCCATTCTT	ACCGGTTCCA	AC 5'

Fig 4

Fig 5

	10	20	30	40	50	60
5'	GGAGGATCCA	ATTATCTGCT	GACTTATAAT	ACTACTAGAA	AGCAAATTTA	AATGACATAT
3'	CCTCCTAGGT	TAATAGACGA	CTGAATATTA	TGATGATCTT	TCGTTTAAAT	TTACTGTATA
	70	80	90	100	110	120
	TTCAATTATA	TCTGAGACAG	CGTGTATAAG	TTTATGTATA	ATCATTGTCC	ATTCTGACT
	AAGTTAATAT	AGACTCTGTC	GCACATATTC	AAATACATAT	TAGTAACAGG	TAAGGACTGA
	130	140	150	160	170	180
	ACAGGTGCCT	ACGGGGAGAT	CGTCTTGACT	CAGTCTCCAG	GCACACTGTC	TCTGAGTCCA
	TGTCCACCGA	TGCCCCCTCTA	GCAGGACTGA	GTCAGAGGTC	CGTGTGACAG	AGACTCAGGT
	190	200	210	220	230	240
	GGAGAAAGAG	CCACACTGTC	CTGCAGGGCC	AGTCAGACCA	TTGGCACAAG	CATACACTGG
	CCTCTTTCTC	GGTGTGACAG	GACGTCCCGG	TCAGTCTGGT	AACCGTGTTT	GTATGTGACC
	250	260	270	280	290	300
	TATCAGCAGA	GACCAGGCCA	GGCCCCAAGG	CTTCTCATAT	ATTATGCTTC	TGAGTCTATC
	ATAGTCGTCT	CTGGTCCGGT	CCGGGGTTCC	GAAGAGTATA	TAATACGAAG	ACTCAGATAG
	310	320	330	340	350	360
	TCTGGCATCC	CTGATAGGTT	TAGTGGCAGT	GGATCAGGGA	CAGATTTTAC	TCTTACAATC
	AGACCGTAGG	GA CTATCCAA	ATCACCCTCA	CCTAGTCCCT	GTCTAAAATG	AGAATGTTAG
	370	380	390	400	410	420
	TCCAGGCTGG	AGCCAGAAGA	TTTCGGCAGT	TATTACTGTC	AACAAAGTAG	TAGCTGGCCG
	AGGTCCGACC	TCGGTCTTCT	AAAGCGTCAG	ATAATGACAG	TTGTTTCATC	ATCGACCGGC
	430	440	450	460	470	480
	CTCACGTTTC	GTCAGGGGAC	CAAGGTCCGAG	ATAAAACGTG	AGTAGAATTT	AAATTTTAAG
	GAGTGCAAGC	CAGTCCCCTG	GTTCCAGCTC	TATTTTGCAC	TCATCTTAAA	TTAAAAATTC

CTTCTT 3'
GAAGAA 5'

Fig 6






Fig 7



8/9




Fig 8




Fig 9

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 92/01583

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C12N15/13; C12P21/08; A61K39/395; //C12N5/10

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System	Classification Symbols
Int.Cl. 5	C12N ; C07K ; A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO,A,9 109 967 (CELLTECH, LTD) 11 July 1991 see claims 1-23 ---	1-7
Y	BLOOD vol. 75, no. 4, 15 February 1990, GRUNE & STRATTON, US pages 1017 - 1023 Herve P;Wijdenes J;Bergerat JP;Bordigoni P;Milpied N;Cahn JY;Clement C;Beliard R;Morel-Fourrier B;Racadot E;et al; 'Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10).' See "Patients and methods"; Discussion --- -/-	1-7

¹⁰ Special categories of cited documents :"A" document defining the general state of the art which is not
considered to be of particular relevance"E" earlier document but published on or after the international
filing date"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)"O" document referring to an oral disclosure, use, exhibition or
other means"P" document published prior to the international filing date but
later than the priority date claimed"T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention"X" document of particular relevance; the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step"Y" document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

18 FEBRUARY 1993

Date of Mailing of this International Search Report

09.03.93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

NAUCHE S.A.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 86, no. 24, December 1989, WASHINGTON US pages 10029 - 10033 QUEEN, C. ET AL.; 'A humanized antibody that binds to the interleukin2 receptor.' see the whole document</p> <p>---</p>	1-7
Y	<p>DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION vol. 71, 1990, BASEL, CH pages 103 - 111 Wijdenes J;Beliard R;Muot S;Herve P;Peters A; 'A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study.' See "Materials and methods"; Discussion</p> <p>---</p>	1-7
Y	<p>WO,A,9 007 861 (PROTEIN DESIGN LABS) 26 July 1990 see the whole document</p> <p>-----</p>	1-7

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

JP 9201583
SA 67370

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18/02/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9109967	11-07-91	AU-A- 6974091	24-07-91
		AU-A- 7033091	24-07-91
		AU-B- 631481	26-11-92
		AU-A- 7048691	24-07-91
		EP-A- 0460167	11-12-91
		EP-A- 0460171	11-12-91
		EP-A- 0460178	11-12-91
		WO-A- 9109966	11-07-91
		WO-A- 9109968	11-07-91
		GB-A- 2246781	12-02-92
		GB-A- 2246570	05-02-92
		JP-T- 4505398	24-09-92
		JP-T- 4506458	12-11-92
WO-A-9007861	26-07-90	AU-A- 5153290	13-08-90
		CA-A- 2006865	28-06-90
		EP-A- 0451216	16-10-91